Nexxt Spine, LLC., a Noblesville, Indiana-based spine device and instrument maker, recently announced the hiring of John Eekhof as Director of Marketing. His responsibilities will include market strategy, product management, strategic communications, cultivating brand awareness, and the launching of products recently cleared through the U.S. FDA 510(k) pathway and those still in the pipeline.
John Eekhof Joins Nexxt Spine as Director of Marketing

Eekhof brings with him over two-and-a-half decades of medical device sales and marking experience from other top companies in the industry. He has worked for both Stryker Corporation and Medtronic plc in leadership roles such as global marketing director for stryker spine and group director – strategic pricing and contracting for medtronic spine and biologics. Most recently Eekhof held the title of northeast regional vice president of sales for Xtant Medical Holdings, Inc. There, he helped to expand the customer base and increased organic revenue.
Nexxt Spine Chief Operating Officer James Abraham shared his thoughts in a recent press release from the company, “We are excited to have John at the helm of the Marketing Department. John brings an extensive background and industry knowledge during a period of tremendous growth for the company. The team looks forward to what can be accomplished under his leadership.”
Nexxt Spine plans to launch its Matrixx and Struxxure anterior lumbar interbody fusion (ALIF) and lateral lumbar interbody fusion (LLIF) interbody and plate systems in Q4 2020 under Eekhof’s oversight.
Eekhof said of his new position, “Nexxt Spine is a unique company in the spine market and I look forward to propelling the brand forward. We are just tapping into the potential the company has to offer to surgeons and distributors alike and the future is bright.”
Nexxt Spine designs and manufactures all of their implants, and nearly all of the instruments that they sell in their Noblesville, Indiana facility.

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.